(Q41730279)

8 October 2017

1 reference

title

Rationale for immune-based therapies for HIV-1 infection (English)

1 reference

8 October 2017

Valdez H

1

1 reference

8 October 2017

Al-Harthi L

series ordinal

2

1 reference

8 October 2017

Landay A

series ordinal

3

1 reference

8 October 2017

Lederman MM

series ordinal

4

1 reference

8 October 2017

publication date

1 March 1998

1 reference

8 October 2017

published in

Translational Research

1 reference

8 October 2017

volume

131

1 reference

8 October 2017

issue

3

1 reference

8 October 2017

page(s)

197-206

1 reference

Prognosis in HIV-1 infection predicted by the quantity of virus in plasma

8 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990090-7

Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990090-7

CD8+ lymphocyte activation at human immunodeficiency virus type 1 seroconversion: development of HLA-DR+ CD38- CD8+ cells is associated with subsequent stable CD4+ cell levels. The Multicenter AIDS Cohort Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990090-7

HIV infection induces changes in CD4+ T-cell phenotype and depletions within the CD4+ T-cell repertoire that are not immediately restored by antiviral or immune-based therapies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990090-7

Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990090-7

Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990090-7

Perturbation of CD4+ and CD8+ T-cell repertoires during progression to AIDS and regulation of the CD4+ repertoire during antiviral therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990090-7

An inducible transcription factor activates expression of human immunodeficiency virus in T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990090-7

Direct interaction of human TFIID with the HIV-1 transactivator tat

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990090-7

Identification of a group of cellular cofactors that stimulate the binding of RNA polymerase II and TRP-185 to human immunodeficiency virus 1 TAR RNA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990090-7

Human immunodeficiency virus type 1 Gag protein binds to cyclophilins A and B

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990090-7

Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990090-7

HIV-1 Entry Cofactor: Functional cDNA Cloning of a Seven-Transmembrane, G Protein-Coupled Receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990090-7

CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990090-7

A pilot study of hydroxyurea among patients with advanced human immunodeficiency virus (HIV) disease receiving chronic didanosine therapy: Canadian HIV trials network protocol 080.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990090-7

Relative resistance to HIV-1 infection of CD4 lymphocytes from persons who remain uninfected despite multiple high-risk sexual exposure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990090-7

Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990090-7

CCR3 and CCR5 are co-receptors for HIV-1 infection of microglia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990090-7

Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. ACTG 241 Protocol Virology Substudy Team

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990090-7

Serum cytokine profiles in acute primary HIV-1 infection and in infectious mononucleosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990090-7

Interleukin 2 production and responsiveness in individuals with acquired immunodeficiency syndrome and the generalized lymphadenopathy syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990090-7

Impaired interleukin 12 production in human immunodeficiency virus-infected patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990090-7

Interleukin 2: the molecule and its function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990090-7

Interleukin-2 enhances the depressed natural killer and cytomegalovirus-specific cytotoxic activities of lymphocytes from patients with the acquired immune deficiency syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990090-7

Prolonged immunostimulatory effect of low-dose polyethylene glycol interleukin 2 in patients with human immunodeficiency virus type 1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990090-7

Efficacy of low doses of the polyethylene glycol derivative of interleukin-2 in modulating the immune response of patients with human immunodeficiency virus type 1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990090-7

Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990090-7

Subcutaneous administration of interleukin-2 in human immunodeficiency virus type 1-infected persons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990090-7

Natural killer (NK) cell stimulatory factor increases the cytotoxic activity of NK cells from both healthy donors and human immunodeficiency virus-infected patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990090-7

Restoration of HIV-specific cell-mediated immune responses by interleukin-12 in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990090-7

In vitro effect of interleukin-12 on antigen-specific lymphocyte proliferative responses from persons infected with human immunodeficiency virus type 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990090-7

T helper type 1/T helper type 2 cytokines and T cell death: preventive effect of interleukin 12 on activation-induced and CD95 (FAS/APO-1)-mediated apoptosis of CD4+ T cells from human immunodeficiency virus-infected persons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990090-7

Interleukin-12 administered in vivo decreases human NK cell cytotoxicity and antibody-dependent cellular cytotoxicity to human immunodeficiency virus-infected cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990090-7

Elevated alpha-tumor necrosis factor levels in spinal fluid from HIV-1-infected patients with central nervous system involvement

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990090-7

Interleukin-1 and tumor necrosis factor-alpha synergistically mediate neurotoxicity: involvement of nitric oxide and of N-methyl-D-aspartate receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990090-7

Correlation of serum cytokine levels with haematological abnormalities in human immunodeficiency virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990090-7

Effect of recombinant human transforming growth factor beta and tumor necrosis factor alpha on bone marrow progenitor cells of HIV-infected persons.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990090-7

Hypertriglyceridemia in the acquired immunodeficiency syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990090-7

Soluble receptors for tumor necrosis factor as predictors of progression to AIDS in asymptomatic human immunodeficiency virus type 1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990090-7

The effect of tenidap on cytokines, acute-phase proteins, and virus load in human immunodeficiency virus (HIV)-infected patients: correlation between plasma HIV-1 RNA and proinflammatory cytokine levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990090-7

Thalidomide as treatment of refractory aphthous ulceration related to human immunodeficiency virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990090-7

Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990090-7

Pentoxifylline for the treatment of infection with human immunodeficiency virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990090-7

Pentoxifylline therapy in human immunodeficiency virus-seropositive persons with tuberculosis: a randomized, controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990090-7

Biological and clinical aspects of interleukin 6.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990090-7

Transplantation of thymic tissue into patients with AIDS. An attempt to reconstitute the immune system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990090-7

HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990090-7

Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990090-7

A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990090-7

HIV-specific cytotoxic T lymphocytes in seropositive individuals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990090-7

AIDS virus-specific cytotoxic T lymphocytes in lung disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990090-7

Effects of adoptive immunotherapy with autologous CD8+ T lymphocytes on immunologic parameters: lymphocyte subsets and cytotoxic activity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990090-7

Clinical and immunological changes in AIDS patients following adoptive therapy with activated autologous CD8 T cells and interleukin-2 infusion.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990090-7

Transfer of HIV-1-specific cytotoxic T lymphocytes to an AIDS patient leads to selection for mutant HIV variants and subsequent disease progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990090-7

Cytoplasmic domains of the interleukin-2 receptor beta and gamma chains mediate the signal for T-cell proliferation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990090-7

T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990090-7

Antiviral effect and ex vivo CD4+ T cell proliferation in HIV-positive patients as a result of CD28 costimulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990090-7

Differential regulation of HIV-1 fusion cofactor expression by CD28 costimulation of CD4+ T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990090-7

Stem cells as vehicles for gene therapy: novel strategy for HIV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990090-7

Gene therapy and immune restoration for HIV disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990090-7

Gene therapy in peripheral blood lymphocytes and bone marrow for ADA- immunodeficient patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990090-7

Engraftment of gene-modified umbilical cord blood cells in neonates with adenosine deaminase deficiency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990090-7

Recombinant soluble CD4 therapy in patients with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase I-II escalating dosage trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990090-7

Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990090-7

inferred from DOI database lookup

7 January 2021

based on heuristic

Interleukin-1 and tumor necrosis factor alpha can be induced from mononuclear phagocytes by human immunodeficiency virus type 1 binding to the CD4 receptor.

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2898%2990090-7

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0022-2143(98)90090-7

1 reference

8 October 2017

1 reference